AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
CareDx, Inc. reports its first net profit in a decade with improved cash flow and margins. Click for this updated look at CDNA stock prospects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback